Evidence map›Paper›PMID 41917406›Full record

ReviewAdvances in experimental medicine and biology2026

Applications of Pseudoviruses Bearing Glycoproteins of SARS-CoV-2 and Influenza Virus.

Makoto Ota, Kaori Sano, Kenji Yoshihara, Shinji Watanabe, Hideki Hasegawa, Kei Miyakawa

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Makoto OtaInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Kaori SanoInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Kenji YoshiharaInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Shinji WatanabeInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Hideki HasegawaInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Kei MiyakawaInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan. keim@niid.go.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review discusses pseudoviruses, which are chimeric viral particles constructed by replacing the envelope glycoproteins of viruses such as human immunodeficiency virus (HIV) or vesicular stomatitis virus (VSV) with those of target viruses, and their advantages in the study of highly pathogenic respiratory viruses. These systems serve as valuable tools for elucidating viral entry mechanisms, screening antiviral drugs, quantitatively assessing virus-neutralizing antibodies, and evaluating vaccine efficacy, while reducing the safety risks associated with live viruses. Despite limitations such as applicability primarily to enveloped viruses, ongoing technological advances continue to improve pseudovirus systems, increasing their utility in vaccine development, antiviral research, and rapid response to emerging infectious diseases.

Indexed as

GlycoproteinsOrthomyxoviridaeSARS-CoV-2Viral EnvelopeVirologyVaccine DevelopmentGlycoproteinsAntiviral researchVaccine development

Identifiers

PMID41917406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.